Levee Medical is a medical device company focused on improving outcomes for prostate cancer surgery patients by reducing post-prostatectomy urinary incontinence. Its lead product, the Voro Urologic Scaffold, is an absorbable implant designed to be placed during prostatectomy to manage bladder neck geometry and maintain urethral length—factors critical to preventing post-operative stress urinary incontinence. The device is investigational, not FDA cleared or approved, and remains in research and development. Levee recently closed a Series B financing totaling more than $14 million including note conversions to advance device development and clinical studies. Proceeds will support ongoing ARID studies and an upcoming U.S. pivotal trial. The company reported ARID enrollment progress—28 patients enrolled at Hospital Nacional in Panama City—and said the device has shown an encouraging safety profile and early continence improvements. Levee Medical is developing the Voro Urologic Scaffold, a bioresorbable device intended to be placed during robotic prostatectomy to treat urinary incontinence. The scaffold is designed to reduce stress on the urinary sphincter by managing bladder neck geometry and maintaining urethral length. The company treated the first participants in a first-in-human study and reported initial safety data. Levee plans to use the $4.3M in Seed funding to support clinical and regulatory efforts and to develop and execute a clinical strategy for the technology. Founded by Bruce Choi and based in Durham, North Carolina, the company focuses on solutions to reduce complications associated with surgical treatment for prostate cancer. Levee Medical is developing the Voro™ Urologic Scaffold, a bioresorbable implant intended to be placed during prostatectomy to treat urinary incontinence. The device is designed to reduce stress on the urinary sphincter by managing bladder neck geometry and maintaining urethral length, which the company cites as the best predictor of post-op incontinence. Voro is the first product Levee plans to bring to market and is not currently available for sale. The company raised USD6.6M in a Series A to advance product development, scale infrastructure, and expand the team. Levee is led by CEO Adam Irving and founder/CTO Bruce Choi. Its work focuses on reducing complications associated with surgical treatment for prostate cancer.

Total raised

$21M

Funding rounds

3

Latest round

Series B

Latest activity

Feb 2025